Table 3.
Bispecific antibody.
| Study drug | target | Cancer types | Status | Clinical trial identifier | Ref. |
|---|---|---|---|---|---|
| Epcoritamab | CD3×CD20 T-cell | Relapsed or Refractory Large B-Cell Lymphoma | phase 1/2 | NCT03625037 | (136) |
| Mosunetuzumab | CD20×CD3 T-cell | relapsed or refractory follicular lymphoma | Phase 2 | NCT02500407 | (137) |
| Talquetamab | CD3×GPRC5D T cell | Multiple Myeloma | Phase 1 | NCT03399799 | (138) |
| Glofitamab | CD20 on B cells and CD3 on T cells | Relapsed or Refractory B-Cell Lymphoma | Phase 1 | NCT03075696 | (139) |
| Teclistamab | BCMA and CD3 on T cells | relapsed or refractory multiple myeloma | Phase 1 | NCT03145181 | (140) |
| JNJ-64407564 | GPRC5DxCD3 T-cell | multiple myeloma | Phase 1 | NCT03399799 | (141) |
| GEN1046 | PD-L1 and 4-1BB | Advanced Refractory Solid Tumors | Phase 1 | NCT03917381 | (142) |
| Odronextamab | CD20 on B cells and CD3 on T cells | CD20-positive B-cell malignancies | Phase 1 | NCT02290951 | (143) |
| cadonilimab | PD-1 and CTLA-4 | advanced solid tumours | Phase 1 | NCT03852251 | (144) |
| Zanidatamab | two non-overlapping domains of HER2 | locally advanced or metastatic HER2-expressing or HER2-amplified cancers | Phase 1 | NCT02892123 | (145) |
| ivonescimab | PD-1 and VEGF | advanced immunotherapy-naive NSCLC | Phase 1 | NCT04900363 | (146) |